ArticleLipids in health and disease2025
Bambi/Akt/Tlr4 axis protects against atherosclerosis by maintaining lipid metabolism homeostasis in macrophages.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsAtherosclerosis is a chronic inflammatory disease driven by dysregulated lipid metabolism and macrophage dysfunction. However, the role of Bmp and activin membrane-binding inhibitor (Bambi), a pseudoreceptor that antagonizes Tgfβ superfamily signaling, in modulating these processes remains incompletely characterized.
methodsAn adenovirus encoding Bambi (Ad-Bambi) was generated and delivered systemically to Apoe−/− mice. Atherosclerosis was induced by high-fat diet feeding for 14 weeks, after which plaque development and macrophage phenotypes were assessed.
resultsBambi overexpression significantly attenuated the aortic atherosclerotic plaques area, promoted a shift in macrophage polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype, and significantly reduced the secretion of key inflammatory cytokines, most notably reducing adhesion G protein-coupled receptor E1 (Adgre1) levels by approximately 40% compared to the control group. In vitro, Bambi overexpression enhanced the lipid metabolic capacity of macrophages, upregulated the cholesterol transporters ATP-binding cassette subfamily A member 1 (Abca1) and ATP-binding cassette subfamily G member 1 (Abcg1), facilitated cholesterol efflux, and suppressed ox-LDL-induced foam cell formation. Transcriptome analysis revealed that Bambi downregulates toll-like receptor 4 (Tlr4) expression via activation of the protein kinase B (Akt) pathway, thereby modulating inflammatory responses and lipid homeostasis in macrophages.
conclusionsThese findings demonstrate that Bambi alleviates macrophage lipid metabolic dysregulation and inhibits foam cell formation through an Akt-dependent signaling mechanism. This suggests that Bambi may exert atheroprotective effect during disease and represents a potential therapeutic target for the prevention or treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.